{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:21:54Z","timestamp":1777630914094,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cllc.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T04:48:21Z","timestamp":1702961301000},"page":"e133-e144.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7642-8797","authenticated-orcid":false,"given":"Yohann","family":"Pilon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merav","family":"Rokah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Seitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni F.","family":"Rayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cools-Lartigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Najmeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sirois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Abdulkarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Ezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Camilleri-Bro\u00ebt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Olivier","family":"Fiset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Sud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ofiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cllc.2023.12.005_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.cllc.2023.12.005_bib0002","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.cllc.2023.12.005_bib0003","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.cllc.2023.12.005_bib0004","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2023.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [published correction appears in J Clin Oncol. 2022 Jun 10;40(17):1965]","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2023.12.005_bib0006","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"10308","key":"10.1016\/j.cllc.2023.12.005_bib0007","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [published correction appears in Lancet. 2021 Sep 23;:]","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cllc.2023.12.005_bib0008","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2023.12.005_bib0009","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2023.12.005_bib0010","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl_4","key":"10.1016\/j.cllc.2023.12.005_bib0011","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2023.12.005_bib0012","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2023.12.005_bib0013","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S1470-2045(21)00405-8","article-title":"Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer","volume":"22","author":"Huynh","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2023.12.005_bib0014","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.athoracsur.2019.03.062","article-title":"Clinical-pathologic correlation and guideline concordance in resectable non-small cell lung cancer","volume":"108","author":"Stokes","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.cllc.2023.12.005_bib0015","first-page":"101","article-title":"New developments in neoadjuvant therapy for lung cancer","volume":"33","author":"Bunn","year":"2019","journal-title":"Oncology (Williston Park)"},{"issue":"9687","key":"10.1016\/j.cllc.2023.12.005_bib0016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cllc.2023.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9928","key":"10.1016\/j.cllc.2023.12.005_bib0018","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.12.005_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.580189","article-title":"SABR-BRIDGE: S tereotactic AB lative R adiotherapy B efore R esection to Avo I d delay for early-stage lun G cancer or oligom E ts during the COVID-19 pandemic","volume":"10","author":"Kidane","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.12.005_bib0020","volume":"5","year":"2021"},{"issue":"5","key":"10.1016\/j.cllc.2023.12.005_bib0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"3","key":"10.1016\/j.cllc.2023.12.005_bib0022","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.athoracsur.2010.05.014","article-title":"Systematic classification of morbidity and mortality after thoracic surgery","volume":"90","author":"Seely","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10.1016\/j.cllc.2023.12.005_bib0023","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2023.12.005_bib0024","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2023.12.005_bib0025","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","volume":"23","author":"Heymach","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2023.12.005_bib0026","doi-asserted-by":"crossref","first-page":"S801","DOI":"10.1016\/j.annonc.2020.08.1437","article-title":"1235TiP perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: the phase III KEYNOTE-671 study","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2023.12.005_bib0027","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2022.07.014","article-title":"Pl03.12 progression free survival and overall survival in Nadim II study","volume":"17","author":"Provencio","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2023.12.005_bib0028","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"31","key":"10.1016\/j.cllc.2023.12.005_bib0029","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2023.12.005_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial [published online ahead of print, 2023 Feb 17]","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:09:42Z","timestamp":1715756982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1525730423002644"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.12.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}